The Effectiveness of Continuous Ketamine Infusion (KONTINUE)

This prospective observational cohort study (n=80) assesses the efficacy of continuous intravenous ketamine infusion, paired with magnesium sulfate, in managing chronic pain.

Chronic pain patients, lasting for more than six months without contraindications to treatment, are eligible for participation. The study, led by Centre Hospitalier Princesse Grace, Monaco, will employ a numerical scale and the Clinical Global Impression of Change (CGI-C) to evaluate long-term effectiveness, alongside secondary measures such as the Neuropathic Pain Symptom Inventory (NPSI), Short Form 12 health survey, and Hospital Anxiety and Depression scale. Evaluation schedules will be conducted at day 15, 30, and 60 post-treatment.

Enrolment commenced on February 22, 2022, with an estimated primary completion date of December 24, 2023, and estimated study completion on February 25, 2024. The study, which targets adults aged 18 years and older, adopts a prospective observational cohort design, with a follow-up duration of six months.

Trial Details

There are different treatment for chronic pain. One possible treatment is intravenous infusions of ketamine.

NCT Number NCT06131970

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.